Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia

We have previously shown clinical activity of a mammalian target of rapamycin (mTOR) complex 1 inhibitor in Waldenstrom macroglobulinemia (WM). However, 50% of patients did not respond to therapy. We therefore examined mechanisms of activation of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR in WM,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Roccaro, Aldo M., Sacco, Antonio, Husu, Emanuel N., Pitsillides, Costas, Vesole, Steven, Azab, Abdel Kareem, Azab, Feda, Melhem, Molly, Ngo, Hai T., Quang, Phong, Maiso, Patricia, Runnels, Judith, Liang, Mei-Chih, Wong, Kwok-Kin, Lin, Charles, Ghobrial, Irene M.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2010
Materias:
Lymphoid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2810978/
https://ncbi.nlm.nih.gov/pubmed/19965685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-07-235747
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares